Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma

Table 6

Univariate analysis (Life table & Logrank) and multivariate analysis (Cox regression) of survival.

Univariate analysis
		Median Survival (months)	Significance
Sex	Male	8	$P=.4$
	Female	9
Age	0–39	9	$P=.03$
	40–59	9
	60+	7
Histology	Leiomyosarcoma	9	Synovial versus the rest $P=.008$
	Synovial	12
	Liposarcoma	11
	Other	7
Disease	Locally Advanced	8	$P=.3$
	Metastatic—single organ	9
	Metastatic—multiple organs	8
Sites of metastases	Involved versus uninvolved
	Lung	7 versus 10	$P=.2$
	Liver	8 versus 8	$P=.5$
	Bone	12 versus 8	$P=.7$
Multivariate analysis
	Relative risk	95% CI	Significance
Histology
Synovial	0.6	0.5–0.9	$P=.005$
Other histology	1.0
Site
Not involved	1.0	1.1–1.7	$P=.01$
Involved	1.4
Chemotherapy
Combination	0.6	0.4–0.9	$P=.004$
Single agent/Phase I	1.0